159 related articles for article (PubMed ID: 30315857)
1. Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane.
Sbiera S; Kendl S; Weigand I; Sbiera I; Fassnacht M; Kroiss M
Mol Cell Endocrinol; 2019 Jan; 480():36-41. PubMed ID: 30315857
[TBL] [Abstract][Full Text] [Related]
2. Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.
Kroiss M; Sbiera S; Kendl S; Kurlbaum M; Fassnacht M
Horm Cancer; 2016 Dec; 7(5-6):345-355. PubMed ID: 27631436
[TBL] [Abstract][Full Text] [Related]
3. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
Sbiera S; Leich E; Liebisch G; Sbiera I; Schirbel A; Wiemer L; Matysik S; Eckhardt C; Gardill F; Gehl A; Kendl S; Weigand I; Bala M; Ronchi CL; Deutschbein T; Schmitz G; Rosenwald A; Allolio B; Fassnacht M; Kroiss M
Endocrinology; 2015 Nov; 156(11):3895-908. PubMed ID: 26305886
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.
Boulate G; Amazit L; Naman A; Seck A; Paci A; Lombes A; Pussard E; Baudin E; Lombes M; Hescot S
Int J Oncol; 2019 Jun; 54(6):2149-2156. PubMed ID: 30942448
[TBL] [Abstract][Full Text] [Related]
5. The GRP78/BiP inhibitor HA15 synergizes with mitotane action against adrenocortical carcinoma cells through convergent activation of ER stress pathways.
Ruggiero C; Doghman-Bouguerra M; Ronco C; Benhida R; Rocchi S; Lalli E
Mol Cell Endocrinol; 2018 Oct; 474():57-64. PubMed ID: 29474877
[TBL] [Abstract][Full Text] [Related]
6. Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
Gagliano T; Gentilin E; Benfini K; Di Pasquale C; Tassinari M; Falletta S; Feo C; Tagliati F; Uberti ED; Zatelli MC
Endocrine; 2014 Dec; 47(3):943-51. PubMed ID: 25096913
[TBL] [Abstract][Full Text] [Related]
7. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S
Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975
[TBL] [Abstract][Full Text] [Related]
8. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD
J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392
[TBL] [Abstract][Full Text] [Related]
9. Liver X receptor inhibition potentiates mitotane-induced adrenotoxicity in ACC.
Warde KM; Schoenmakers E; Ribes Martinez E; Lim YJ; Leonard M; Lawless SJ; O'Shea P; Chatterjee KV; Gurnell M; Hantel C; Dennedy MC
Endocr Relat Cancer; 2020 Jun; 27(6):361-373. PubMed ID: 32276262
[TBL] [Abstract][Full Text] [Related]
10. A novel heat shock protein 90 inhibitor potently targets adrenocortical carcinoma tumor suppression.
Wang T; Subramanian C; Blagg BSJ; Cohen MS
Surgery; 2020 Jan; 167(1):233-240. PubMed ID: 31561992
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.
Xu Y; Dong B; Huang J; Kong W; Xue W; Zhu Y; Zhang J; Huang Y
Oncotarget; 2016 Jan; 7(3):3233-44. PubMed ID: 26673009
[TBL] [Abstract][Full Text] [Related]
12. CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis.
Ren L; Yang Y; Li W; Zheng X; Liu J; Li S; Yang H; Zhang Y; Ge B; Zhang S; Fu W; Dong D; Du G; Wang J
J Transl Med; 2022 Oct; 20(1):444. PubMed ID: 36184616
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics.
Zhang J; Wu L; Su T; Liu H; Jiang L; Jiang Y; Wu Z; Chen L; Li H; Zheng J; Sun Y; Peng H; Han R; Ning G; Ye L; Wang W
Front Endocrinol (Lausanne); 2024; 15():1365321. PubMed ID: 38779454
[TBL] [Abstract][Full Text] [Related]
14. CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells.
Germano A; Saba L; De Francia S; Rapa I; Perotti P; Berruti A; Volante M; Terzolo M
PLoS One; 2018; 13(5):e0196931. PubMed ID: 29734384
[TBL] [Abstract][Full Text] [Related]
15. Mitotane for adrenocortical carcinoma treatment.
Hahner S; Fassnacht M
Curr Opin Investig Drugs; 2005 Apr; 6(4):386-94. PubMed ID: 15898346
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
Creemers SG; van Koetsveld PM; van den Dungen ES; Korpershoek E; van Kemenade FJ; Franssen GJ; de Herder WW; Feelders RA; Hofland LJ
J Clin Endocrinol Metab; 2016 Dec; 101(12):4574-4584. PubMed ID: 27603910
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines.
Germano A; Rapa I; Volante M; Lo Buono N; Carturan S; Berruti A; Terzolo M; Papotti M
Mol Cell Endocrinol; 2014 Jan; 382(1):1-7. PubMed ID: 24018612
[TBL] [Abstract][Full Text] [Related]
18. In vitro antitumor activity of progesterone in human adrenocortical carcinoma.
Fragni M; Fiorentini C; Rossini E; Fisogni S; Vezzoli S; Bonini SA; Dalmiglio C; Grisanti S; Tiberio GAM; Claps M; Cosentini D; Salvi V; Bosisio D; Terzolo M; Missale C; Facchetti F; Memo M; Berruti A; Sigala S
Endocrine; 2019 Mar; 63(3):592-601. PubMed ID: 30367443
[TBL] [Abstract][Full Text] [Related]
19. The aurora kinase inhibitor AMG 900 increases apoptosis and induces chemosensitivity to anticancer drugs in the NCI-H295 adrenocortical carcinoma cell line.
Borges KS; Andrade AF; Silveira VS; Marco Antonio DS; Vasconcelos EJR; Antonini SRR; Tone LG; Scrideli CA
Anticancer Drugs; 2017 Jul; 28(6):634-644. PubMed ID: 28410270
[TBL] [Abstract][Full Text] [Related]
20. Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma.
Germano A; Rossin D; Leoni V; Iaia N; Saba L; Basile V; Puglisi S; Caccia C; Poli G; Biasi F; Terzolo M
Cells; 2020 Apr; 9(4):. PubMed ID: 32260362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
